CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Calcipotriene plus betamethasone dipropionate ointmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00817219
NCT00817219Phase 2Completed
CompareCT.gov

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

LEO Pharma·interventional·Posted Jan 6, 2009·Updated Mar 12, 2025

In Brief

A Phase 2 clinical trial evaluating Calcipotriene plus betamethasone dipropionate ointment for Psoriasis Vulgaris. Completed, enrolled 33 participants across 8 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of 4 weeks of TACLONEX ointment in adolescent patients with psoriasis vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 6, 2009
Enrollment StartJul 1, 2009
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17.5 years ago

Interventions

Calcipotriene plus betamethasone dipropionate ointmentdrug

Once daily application for 4 weeks